173 related articles for article (PubMed ID: 10958795)
1. Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism.
Ha TU; Segev DL; Barbie D; Masiakos PT; Tran TT; Dombkowski D; Glander M; Clarke TR; Lorenzo HK; Donahoe PK; Maheswaran S
J Biol Chem; 2000 Nov; 275(47):37101-9. PubMed ID: 10958795
[TBL] [Abstract][Full Text] [Related]
2. Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.
Barbie TU; Barbie DA; MacLaughlin DT; Maheswaran S; Donahoe PK
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15601-6. PubMed ID: 14671316
[TBL] [Abstract][Full Text] [Related]
3. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
4. Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway.
Segev DL; Ha TU; Tran TT; Kenneally M; Harkin P; Jung M; MacLaughlin DT; Donahoe PK; Maheswaran S
J Biol Chem; 2000 Sep; 275(37):28371-9. PubMed ID: 10874041
[TBL] [Abstract][Full Text] [Related]
5. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
7. Effect of human recombinant mullerian inhibiting substance on isolated epithelial and mesenchymal cells during mullerian duct regression in the rat.
Tsuji M; Shima H; Yonemura CY; Brody J; Donahoe PK; Cunha GR
Endocrinology; 1992 Sep; 131(3):1481-8. PubMed ID: 1505479
[TBL] [Abstract][Full Text] [Related]
8. Müllerian inhibitory substance induces growth of rat preantral ovarian follicles.
McGee EA; Smith R; Spears N; Nachtigal MW; Ingraham H; Hsueh AJ
Biol Reprod; 2001 Jan; 64(1):293-8. PubMed ID: 11133686
[TBL] [Abstract][Full Text] [Related]
9. Müllerian inhibiting substance blocks the protein kinase A-induced expression of cytochrome p450 17alpha-hydroxylase/C(17-20) lyase mRNA in a mouse Leydig cell line independent of cAMP responsive element binding protein phosphorylation.
Laurich VM; Trbovich AM; O'Neill FH; Houk CP; Sluss PM; Payne AH; Donahoe PK; Teixeira J
Endocrinology; 2002 Sep; 143(9):3351-60. PubMed ID: 12193547
[TBL] [Abstract][Full Text] [Related]
10. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
[TBL] [Abstract][Full Text] [Related]
11. Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.
Stephen AE; Pearsall LA; Christian BP; Donahoe PK; Vacanti JP; MacLaughlin DT
Clin Cancer Res; 2002 Aug; 8(8):2640-6. PubMed ID: 12171896
[TBL] [Abstract][Full Text] [Related]
12. Müllerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung.
Catlin EA; Tonnu VC; Ebb RG; Pacheco BA; Manganaro TF; Ezzell RM; Donahoe PK; Teixeira J
Endocrinology; 1997 Feb; 138(2):790-6. PubMed ID: 9003016
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo.
Parry RL; Chin TW; Epstein J; Hudson PL; Powell DM; Donahoe PK
Cancer Res; 1992 Mar; 52(5):1182-6. PubMed ID: 1531323
[TBL] [Abstract][Full Text] [Related]
14. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A
Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642
[TBL] [Abstract][Full Text] [Related]
15. Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo.
Chin TW; Parry RL; Donahoe PK
Cancer Res; 1991 Apr; 51(8):2101-6. PubMed ID: 2009529
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of steroidogenesis in Leydig cells by Müllerian-inhibiting substance.
Fynn-Thompson E; Cheng H; Teixeira J
Mol Cell Endocrinol; 2003 Dec; 211(1-2):99-104. PubMed ID: 14656482
[TBL] [Abstract][Full Text] [Related]
17. Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line.
Fuller AF; Guy S; Budzik GP; Donahoe PK
J Clin Endocrinol Metab; 1982 May; 54(5):1051-5. PubMed ID: 6895900
[TBL] [Abstract][Full Text] [Related]
18. Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.
Segev DL; Hoshiya Y; Hoshiya M; Tran TT; Carey JL; Stephen AE; MacLaughlin DT; Donahoe PK; Maheswaran S
Proc Natl Acad Sci U S A; 2002 Jan; 99(1):239-44. PubMed ID: 11773638
[TBL] [Abstract][Full Text] [Related]
19. Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.
Renaud EJ; MacLaughlin DT; Oliva E; Rueda BR; Donahoe PK
Proc Natl Acad Sci U S A; 2005 Jan; 102(1):111-6. PubMed ID: 15618407
[TBL] [Abstract][Full Text] [Related]
20. Mullerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-beta superfamily.
Wilson CA; di Clemente N; Ehrenfels C; Pepinsky RB; Josso N; Vigier B; Cate RL
Mol Endocrinol; 1993 Feb; 7(2):247-57. PubMed ID: 8469238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
